- Bora Pharmaceuticals announces a strategic investment in Tanvex Biopharma, merging their biomanufacturing facilities to create a global biologics CDMO platform.
- The transaction, expected to close in Q1 2025, will make Bora the largest shareholder of Tanvex with a 30.5% stake.
Bora Pharmaceuticals Co., Ltd. has announced a strategic investment in Tanvex Biopharma Co., Ltd., aimed at combining their biomanufacturing facilities to offer a global solution for biologics development and supply. The investment will result in Bora holding approximately 30.5% of Tanvex’s outstanding shares, making it the largest shareholder. This transaction is expected to be completed in the first quarter of 2025.
Bora Pharmaceuticals, a global CDMO with 10 advanced facilities worldwide, will collaborate closely with Tanvex to leverage their combined capabilities. The merger will enhance their ability to provide comprehensive solutions to biologics customers, including Bora’s new fill/finish capabilities in Maryland, USA. Tanvex, with biomanufacturing operations in the USA and Taiwan, adds over 100,000 square feet of biomanufacturing space and large-scale bioreactors to this partnership, complementing Bora’s existing infrastructure.
Bobby Sheng, Chairman and CEO of Bora Group, emphasized that the investment aligns with both companies’ shared vision for the biologics CDMO business. “It combines Bora’s strong reputation, industry-leading quality, and global operational resources with Tanvex’s established USFDA-approved commercial-scale biologics facility,” Sheng stated.
Tanvex CEO Henry Chen noted that this partnership is an ideal opportunity to combine their expertise with Bora’s proven success in building a global CDMO platform. The merged entity aims to address evolving industry demands and capitalize on new opportunities driven by policy changes in the US, such as the BIOSECURE Act.
 Overview of outsourcing trends 
